You are here

Randomization, Placebo-Controlled Dosage Stage of Phase III Trial Completed for Ampligen in Chronic Fatigue Syndrome

Philadelphia, PA, Friday, January 30, 2004: Hemispherx Biopharma, Inc. (AMEX: HEB) announced today that it completes this week the randomization and placebo-controlled dosage stage of its Phase 3 clinical trial for Chronic Fatigue Syndrome (CFS), becoming the first pharmaceutical company to complete a pivotal trial in this disease category, which affects more than 500,000 Americans. The Company expects to present clinical data from this study in the second quarter of this year.

The clinical trial is a multi-center, double-blind, randomized, placebo-controlled Phase 3 pivotal study of the efficacy and safety of the experimental agent Ampligen® versus placebo in patients with severely debilitating Chronic Fatigue Syndrome (CFS).

The Company believes that efficacy will be established by showing medically and statistically significant improvement of the primary endpoint which is improved physical performance as measured by Treadmill Exercise Tolerance Testing (ETT): Duration. Efficacy may be established by showing a medically significant increase (≥ 6.5%) in mean exercise duration (baseline compared to week 40) that is statistically significant (p≤ 0,05) using analysis of covariance of log10 transformed data with Baseline ETT duration as covariate. The Company will also analyze the median absolute changes in ETT duration between termination and baseline using the Mann Whitney test. The secondary endpoints of the study are various other indices of physical performance and cognitive activity.

About Chronic Fatigue Syndrome
CFS is defined by various governmental agencies as a serious debilitating disease in which patients suffer complex symptoms, including profoundly disabling fatigue, flu-like symptoms, headaches, sore throat, joint and muscle pain, mental fogginess, depression and sleep disorders. The U.S. Center for Disease Control and Prevention has added CFS to its top priority list of emerging infectious diseases. CFS is estimated to affect over 500,000 people in the U.S., and an equal number in Europe. At present, there is no other specific treatment available for CFS and no alternative drug appear to be under development in recognized clinical trials.

About Ampligen
Ampligen® is an experimental, double stranded RNA drug acting potentially as an immunomodulator and antiviral. Based on in vitro studies, Ampligen® is believed to stimulate the immune system as well as inhibit the virus directly. The experimental product is currently in a Phase 3 clinical trial for the potential treatment of CFS and in two Phase 2b clinical trials for the potential treatment of HIV/AIDS. Treatment IND status for Ampligen® and CFS has already been recognized by various regulatory bodies.

Source: Hemispherx Biopharma, Inc.

Recent Headlines

NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Attacks Cancerous Cells, Leaves Healthy Tissues Alone
Moderates Pre-diabetes Progression, Reduces Cholesterol Levels